Abpro Holdings (ABPO) Non-Current Deferred Tax Liability (2023 - 2024)
Abpro Holdings' (ABPO) quarterly Non-Current Deferred Tax Liability came in at $3.2 million in Q4 2024, down 27.2% YoY from $4.4 million in Q1 2024, and down 27.2% on a QoQ basis from $4.4 million in Q4 2023.
Abpro Holdings (ABPO) Non-Current Deferred Tax Liability (2023 - 2024) Analysis & Trends
Abpro Holdings (ABPO) has 2 years of Non-Current Deferred Tax Liability data on file, last reported at $3.2 million in Q4 2024.
- Quarterly Non-Current Deferred Tax Liability fell 27.2% year-over-year to $3.2 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $3.2 million (down 27.2% YoY) and the FY2024 annual result came in at $3.2 million, down 27.2% from the prior year.
- Non-Current Deferred Tax Liability fell to $3.2 million in Q4 2024, from $4.4 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $4.4 million in Q4 2023 to a low of $3.2 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Abpro Holdings | 1.14 Mn | 1.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 3.22 Mn |
| Dec 31, 2024 | 3.22 Mn |
| Dec 31, 2023 | 4.42 Mn |
| Dec 31, 2023 | 4.42 Mn |